This article is a correction to:
Wuzi Yanzong Pill—Based on Network Pharmacology and In Vivo Evidence—Protects Against Spermatogenesis Disorder via the Regulation of the Apoptosis Pathway
Wang-qiang Chen1†
Cai-fei Ding
Jian-xiong Ma- 1Department of Reproductive Medicine, Zhejiang Provincial Integrated Chinese and Western Medicine Hospital, Hangzhou, China
- 2The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, China
- 3Department of Andrology, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing, China
by Chen W, Ding C, Yu J, Wang C, Wan L, Hu H and Ma J (2020). Front. Pharmacol. 11:592827. doi: 10.3389/fphar.2020.592827
In the published article, there was an error in Figures 4, 6 as published. The images in Figure 4D and the immunohistochemical staining of Bcl-XL in Figure 6 were mistakenly swapped. The corrected Figures 4, 6 appear below.
FIGURE 4
FIGURE 4. Compounds identification and the effect of the WZYZP on the experimental spermatogenesis disorder model rats. (A) The phytochemical compositions identification in the WZYZP by UHPLC-Q-TOF/MS in the positive ion mode and negative ion mode. (B) Effect of the WZYZP on sperm counts and motility. (C) Effect of WZYZP on serum hormone levels of T, FSH levels were detected with an ELISA assay. (D) HE staining to evaluate the effect of the WZYZP on rat testes histological changes. Above, magnification ×200, 400. (E) TUNEL staining for the evaluation of cell apoptosis. Above, magnification ×200. #p < .05 vs. Model group, ##p < .01 vs. Model group.
FIGURE 6
FIGURE 6. Effect of the WZYZP on the expression levels of Bcl-XL and Bax in testes tissues. The expression levels of Bcl-XL and Bax in the testes were determined by immunohistochemistry analysis. Above, magnification ×200, 400. #p < .05 vs. Model group, ##p < .01 vs. Model group.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: Wuzi Yanzong pill, spermatogenesis disorder, network pharmacology, bioactive compounds, hub targets, apoptosis pathway
Citation: Chen W-q, Ding C-f, Yu J, Wang C-y, Wan L-y, Hu H-m and Ma J-x (2023) Corrigendum: Wuzi Yanzong pill—Based on network pharmacology and In Vivo evidence—Protects against spermatogenesis disorder via the regulation of the apoptosis pathway. Front. Pharmacol. 13:1129448. doi: 10.3389/fphar.2022.1129448
Received: 22 December 2022; Accepted: 28 December 2022;
Published: 12 January 2023.
Edited and reviewed by:
Ke-Wu Zeng, Health Science Centre, Peking University, ChinaCopyright © 2023 Chen, Ding, Yu, Wang, Wan, Hu and Ma. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Jian-xiong Ma, reproductivedcf@sina.com
†These authors have contributed equally to this work